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Abstract 
With menadione and cyclopentadiene as starting materials, a menadione-cyclopentadiene adduct 
was synthesized via a Diels-Alder reaction. ?????reaction serves as the first step in a pathway to 
synthesize a menadione-safranal derivative that could potentially have antioxidant activity. 
Introduction 
Menadione, also known as 2-methylnapthalene-1,4-dione, is a yellow crystalline solid 
that is used in fungicides and as a vitamin K supplement in medicine and animal feed. 1 
Menadione is known as synthetic vitamin K3 as well. Its derivatives have been shown to 
possibly aid in cancer treatment and are used to understand how cell mechanisms work. The 
function of menadione has been studied in many different cases. One study has shown that 
derivatives of menadione could possibly be ''potent reversible and uncompetitive inhibitors" of 
glutathione reductases. These reductases have been shown to have "anticancer and antimaJarial 
activity" and could possibly "contribute to the reversal of drug resistance. "2 Glutathione is a 
strong anti-oxidant and plays a major role in homeostasis. Oxidized glutathione is currently 
being studied in relation to breast cancer by the U.S National Institutes of Health to see if it 
"stimulates the immune system in different ways" to inhibit tumor cell growth. 3 
Currently, menadione is being tested as a topical lotion to treat epidermal-growth-factor-
receptor (EGFR) inhibitor associated rash. The rash is a side effect of EGFR inhibitors being 
used to treat non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal, head, and neck 
cancer.4 
Menadione has also been found to induce oxidative stress. According to the German 
Research Center for Environmental Health, oxidative stress occurs when ''the equilibrium in the 
) 
organism moves towards oxidative processes." Oxidative stress is involved with the aging of 
body cells, and it also induces cell death. The buildup of reactive oxygen species and the 
oxidation of biomolecules causes many diseases. This may be significant in "inducing growth 
inhibition" of cancer celllines.6 In research done at Anjou University in South Korea, studies 
have found that menadione-induced cell death in cultured C2 myoblasts. 7 Menadione also 
inhibits intestinal calcium absorption by playing a role in mitochondrial dysfunction.8 
Menadione itself is toxic and causes injury to cells. It is lipid soluble and ''promotes the 
hepatic biosynthesis of blood clotting factors." Menadione is carcinogenic. However, cells 
treated with menadione and metabolic activation factors could "cause DNA damage and repair'' 
without carcinogenicity.9 This may be key in finding alternative treatments for cancer. 
In addition, menadione exhibits anti estrogenic activity in an in vitro assay. This has been 
achieved by the suppression of hepatic estrogen response genes. This may also have the same 
function in vivo. 10 
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Menadione has many different activities and is involved in inducing or inhibiting many 
different cell functions. Studies affirm menadione's versatility. If menadione alone can achieve 
these different functions in the cell, then derivatives of menadione also have the same potential. 
These derivatives may have great effects as anti-cancer agents. 
The synthesis of a menadione derivative could be significant because many are interested 
in its function as a means of treating cancer. It is known that there are two different methods of 
adding substituents to menadione to form menadione derivatives. Substituents may be added via 
radical decarboxylation and via a Diels-Alder reaction. The Diels-Alder method was chosen to 
"activate the bridgehead hydrogen for alkylation" in order to add safranal that will yield the 
menadione derivative ultimately. 11 
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The target compound is an intermediate to the following menadione derivative 
The article entitled "Improved Synthesis of Vitamin K'' by Ya-Fei ]i, Ahi-Min Zong, and 
Xian-Yong Wei in 2003 was used as a model and followed closely for the beginning reactions in 
the synthesis ofthe menadione derivative.11 
Menadione was sought to be combined with safranal due to its anti-oxidant activity. 
Safranal is derived from saffron which is a spice from the stigmas of crocus flowers (Crocus 
sativus). It has been found that safranal inhibits cell growth of human tumor cells. Studies were 
done on HeLa cells which exhibited 50% growth inhibition.12 According to the Centre for 
Cancer Education, HeLa cells are a line of human epithelial cells derived from the cervical 
carcinoma of Henrietta Lacks. These cells proliferate abnormally rapidly.13 Safranal has a high 
radical scavenging activity which means that it is highly involved in aging processes, anti-
inflammatory, anti-cancer, and wound-healing activity.14 With anti-cancer activity or inhibition 
of certain cell mechanisms in each piece of the menadione derivative, there may be added anti-
cancer activity with the pieces together in one compound 
+ 
Scheme 1. Proposed Reaction 
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Experimental Details 
In the first trials, the synthesis of the intermediate product (also known as the menadione-
cyclopentadiene adduct) was attempted. 3.0408 g (0.0177mol) of menadione was dissolved in 
30 mL of glacial acetic acid in a beaker. Seven microspatula scoops of a Lewis Acid catalyst 
AlC?? (purple/white solid) were added to the dark, transparent yellow solution. After the addition 
of the catalyst, the solution became cloudy and turned dark yellow as the ??????dissolved. 4 mL 
(0.049 mol) of excess cyclopentadiene (cracked from dicyclopentadiene a few months prior) was 
then added to the solution. 
The solution was left to stir with a magnetic stir bar in a 150mL beaker for three days. 
The beaker was covered with a watch glass to prevent evaporation of solvent After one day of 
stirring, the solution became a dark yellow-brown opaque solution. After the 3rd day, the 
solution was completely brown and cloudy. When taken off the magnetic stirrer, the solution 
separated with a darker brown layer on top of the cloudy brown layer. 
Half of the organic intermediate product (around 17 mL) was then isolated using a 
separatory funnel, ~25 mL of reverse osmosis-purified water, and approximately 40 mL diethyl 
ether. Only half was separated out because this method was not performed in the literature. This 
route was a faster way to rid the product of the acetic acid solvent, which has a high boiling point 
and is hard to evaporate. The organic layer was washed three times with water and the yellow 
aqueous layer was extracted. Sodium sulfate was then added to the organic solution to get rid of 
excess water. Afterward, the brown solution was collected in a 50 mL round-bottom flask. The 
diethyl ether was then removed by rotary evaporation with Rotovapor Buchi REJJJ. 
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After evaporation of the solvent, the brown solid was recrystallized using methanol as the 
solvent. It was then vacuum filtered for 3 hours. Its melting point was 96-98"C as measured by 
a MEL TEMP melting point device. 
IR spectroscopy of the product dissolved in methylene chloride was performed using 
Nicolet IR200 FI'-IR instrument and direct path methodology. The peaks were found at 1666 
cm·1, 1596 cm·1, 1596 cm·1, 1301 cm·1 (Figure 3). The spectrum was very close to the literature 
observations but also similar to the menadione spectrum exhibiting peaks at 1664 cm·1, 1593 em· 
1
, and 1301 em -1 (Figure 1). The spectrum of cyclopentadiene was also measured (Figure 2). 
Gas Chromatography-Mass Spectroscopy was performed using the Agilent Technology 
6890N GC System on this product, and it was found that there was a large peak for the molecular 
weight of menadione 172 g. There were also significant peaks that showed up later giving peaks 
at 416.4 g and 430. 4 g (Figures 6-8). A small peak was observed at the targeted molecular 
weight 238 g for the menadione-cyclopentadiene adduct (Figure 8). However, its magnitude 
was very small. 
The reaction was then attempted again using freshly cracked cyclopentadiene. An 
apparatus was set up to collect cyclopentadiene (a colorless semi-transparent liquid) from 
dicyclopentadiene (a dark, brown/orange liquid). 3.0260 g (0.0176 mol) of menadione was 
combined with 4 mL (0.049 mol) cold excess cyclopentadiene and 30 mL glacial acetic acid was 
the solvent. The same protocol was performed as in the previous trial. The reaction was left to 
react for two weeks. 
The product was a lot browner than the previous reaction, almost black. It was 
recrystallized with methanol and the resulting crystals were light brown and needles. Some 
yellow/brown flat flakes (thin) were also observed in the dried product. The product was 
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recrystallized again and a smaller amount of brown solid resulted. Its melting point was found to 
be 95-98"C. Activated charcoal was used in the recrystallization to rid the mixture of more 
impurities. Very little product was recovered, however. The charcoal and undissolved solid 
during recrystallization was filtered with a funnel and filter paper. The IR spectra exhibited 
peaks at 1665 cm"1 and 2360 cm-1• GC-MS analysis was performed, and it showed a large peak 
at 172 g, the molecular weight of menadione (Figure 6 and 11). There were no peaks for 
products of higher molecular weight near the targeted molecular weight. Figures 5 and 9 
illustrate the peaks of greatest magnitude in two different reaction trials. Figures 10 and 11 
indicate which compound fragments were predominant. 
A third trial was attempted using 3.2204 g (0.0187 mol) menadione and 4 mL excess 
cyclopentadiene. The same protocol was again performed, however, this time the mixture 
reacted for three days. Yellow and brown solids were separated out during recrystallization. 
The yellow solid had a melting point of 58-60"C while the brown/black solid had a melting point 
of?50-55·c. 
A fourth trial was attempted this time using a newer bottle of catalyst AlC?? 3.018 g 
(0.0175 mol) menadione was added to -5 mL (0.0607 mol) of cyclopentadiene. The newer 
catalyst was a lighter yellow, powdery solid. The same protocol was followed. After the 
addition of ???????the solution turned green. The addition of the catalyst prompted an exothermic 
reaction. The solution became darker green and opaque. It then became black. 
The reaction mixture was performed under the hood and left to stir overnight with a 
magnetic stir bar. The black solution then began to have a hint of dark purple. The reaction was 
left to react for three days. The dark purple/black solution had clumps of dark solid granules. 
The beaker was placed over the magnetic stirrer to dissolve the solid. It became a liquid 
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consistency. It was then poured into a separatory funnel for organic extraction and to wash away 
the acetic acid. Upon addition of reverse osmosis-purified water, a purple/black solid 
precipitated. The solid was then removed from the separatory funnel for recrystallization. 
Diethyl ether was added to the separatory funnel to salvage any other product in the solution; 
however, not much was recovered. 
An attempt was made to recrystallize the black solid in methanol, but it did not dissolve 
very well. Instead, it became a hard, tar like substance. Methylene chloride was then added to 
the mixture. It did not dissolve the solid right away. The solid softened mostly and became a 
dark purple/black, oily liquid in methylene chloride. The solid did not behave like the product of 
previous reactions. 
Results and Discussion 
Table 1. Characterization of starting materials and product 
Compound Melting Point Appearance 
Menadione Yellow powder 
Cyclopentadiene Clear liquid 
Menadione-cyclopentadiene (Trial 1) Brown solid 
Menadione-cyclopentadiene (Trial2) 95-98"C Brown solid 
The intermediate product was reported to be a white solid11• The Diels-Alder reaction 
did not occur in the first trial because the cyclopentadiene that had been shelved for a few 
months dimerized. This was concluded after a Diels-Alder test reaction was performed with the 
older cyclopentadiene and maleic anhydride. No solid was formed in the test reaction. Solid 
would have formed, however, with the monomer cyclopentadiene. In addition, the IR spectrum 
of the older cyclopentadiene was similar to the spectrum of the dimer dicyclopentadiene. What 
may have occurred was some unknown side reaction between the dimer and the menadione. 
The targeted Diels-Alder reaction was only possible with the monomer cyclopentadiene 
obtained from freshly cracked dicyclopentadiene. It too produced a brown solid but different 
than the previous collected product The solid produced in this experiment was brown possibly 
due to some impurities and poor technique in recrystallization. All the impurities may not have 
been completely removed as the recrystallized product was washed and filtered. Though its 
melting point was in agreement with the literature value of97-98°C (See Table 1 above), the 
color differed. Also, the mass spectrum did not show a large peak at the desired molecular 
weight of238.27 g. 
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However, peaks were observed at molecular weights of 416 g and 430 g for the first trial 
product These fragments indicate some other reaction may have occurred. The dimer may have 
reacted somehow producing some adduct of the dimer and menadione. The magnitude of the 
peaks at 172 g (Figures 6 and 11) was great, possibly indicating unreacted menadione in the 
products or the menadione component of the fragmented product. The GC-MS data for the trial 
with the newly cracked cyclopentadiene indicated that there were no significant peaks at the 
targeted molecular weight The high heat of the GC-MS also could have induced a reverse 
Diels-Alder reaction, resulting in the absence of higher molecular weight ???????????
The IR data indicate that menadione, the starting material, is comparable to the product. 
Their fingerprint regions do share similar peaks. There are no sp3 C-H peaks in the menadione 
spectrum but there are both sp2 and sp3 C-H peaks in the product spectrum (Figure 3) ofTrial1 
indicating C-H double bonds and C-H single bonds as part of an adduct of the dimer and 
menadione. 
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It was realized that a catalyst was necessary to mediate the Diels-Alder reaction. This is 
due to the high activation energy required to attach cyclopentadiene onto menadione to form a 
multi-cyclic compound. The carbonyl groups on menadione are electron-withdrawing groups 
making it a good, reactive dienophile or "lover of dienes." However the methyl group on 
menadione, an electron-donating group, could lessen the reactivity of menadione. It was also 
discovered that a new bottle of catalyst prompted a different product and reaction than the older 
catalyst. The newer ??????was better able to decrease the activation energy needed to increase 
the rate of the Diels-Alder reaction. A better catalyst greatly influences the rate of reaction. 
A different separation technique was used to isolate the organic product because it took 
over three hours to remove the acetic acid solvent. Evaporating acetic acid takes an inordinate 
amount of time, so separating the organic layer first with diethyl ether is more efficient. There 
are many factors that influence this reaction. 
Conclusion 
The intermediate product formed is only a precursor to the desired target menadione 
derivative. In succeeding experiments, adding safranal to the adduct can be attempted. The 
accuracy of the melting point shows that the synthesized product is very similar to the literature 
value except in appearance. However, analysis of the GC-MS spectra shows that there may also 
be another reaction that may have occurred. 
In future work, the purity of the starting materials should be tested first. Due to the 
minimal product yield after recrystallization, the experiment could be performed on a bigger 
scale. More research time is necessary to make definitive conclusions about the product. 
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